A Study of DS-7011a in Patients With Systemic Lupus Erythematosus
| 适应症 | Systemic Lupus Erythematosus |
|---|---|
| 分期 | 1/2期 |
| 申办方 | Daiichi Sankyo |
| 状态 | 已完成 |
| 受试者人数 | 26 人 |
| 干预（药物） | DS-7011a |
| 开始日期 | 2023年6月7日 |
| 完成日期 | 2025年4月1日 |
| 结果公布日 | 2026年5月28日 |
摘要
Systemic lupus erythematosus (SLE) is a systemic chronic autoimmune disease characterized by autoantibody production, inflammation, and tissue damage in multiple organs. Standard of care therapies used to treat SLE are only partially effective and have a wide range of toxicities. There is a need for more effective and safer therapies for patients with SLE.
Number of Participants With Treatment-emergent Adverse Events Following Administration With DS-7011a in Participants With Systemic Lupus Erythematosus
| DS-7011a | 11 Participants |
|---|---|
| Placebo | 4 Participants |
在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文
同一适应症的其他试验
- Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacok — Viatris Innovation GmbH
- Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With — Viatris Innovation GmbH
- A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2 — Hoffmann-La Roche
- Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults — Duke University
- Reducing Disparities in Medication Adherence in SLE — Duke University
- Using the Cholinergic Anti-Inflammatory Pathway to Treat Systemic Lupus Musculoskeletal Pa — Northwell Health